• Hyoscine N butylbromide has a peripheral anticholinergic action which results from a ganglion-blocking action within the visceral  wall as well as from an anti-muscarinic activity. Consequently, it exerts a spasmolytic action on the smooth muscles of the gastrointestinal, biliary and genito-urinary tracts.
  • As a quaternary ammonium derivative, Hyoscine N butyl-bromide does not readily pass the blood-brain barrier; therefore, anticholinergic side effects at the central nervous system do not occur when used in therapeutic doses.

Each film coated tablet of Busconil® 10 contains:

  • Hyoscine N butylbromide                       10 mg

Each 5 ml of Busconil® oral solution contains:

  • Hyoscine N butylbromide                        5 mg

Busconil® is mainly indicated in the following cases:

  • Gastrointestinal tract spasm (including pylorospasm).
  • Hypermotility and postoperative vomiting and spastic constipation.
  • Spasm and dyskinesia of the biliary system.
  • Genito-urinary tract spasm.
  • Spastic pain in dysmenorrhoea and nocturnal enuresis.
  • Delayed relaxation of the lower uterine segment.
  • Peptic ulcer in conjunction with antacids or H2-receptor antagonists.

Busconil® is contraindicated in the following cases: 

  • Hypersensitivity to Hyoscine N butyl bromide or any anticholinergic drugs.
  • Myasthenia gravis and megacolon.
  • Tachycardia and myocardial Ischemia.
  • Narrow angle glaucoma, adhesions between the Iris and lens.
  • Gastrointestinal obstructive disease, paralytic ileus,  ulcerative colitis and hepatic diseases.
  • Obstructive uropathy and renal diseases.
  • The effect of Busconil® may be enhanced by concomitant administration of other drugs with antimuscarinic properties such as: Amantadine, Tricyclic antidepressants, Quinidine, some Antihistamines, Phenothiazine and Antipsychotics.
  • Concomitant treatment with Dopamine antagonist such as Metoclopramide may result in diminution of the effects of both drugs on the gastrointestinal tract.
  • Caution is recommended in pregnancy especially during the first trimester.
  • Safety during lactation has not yet been established.However, adverse effects on the new born have not been reported.
  • The side effects are dose-related and usually reversible when therapy is discontinued.

At therapeutic doses, adverse effects include:

  • dryness of mouth and skin, thirst, flushing, dilated pupils with loss of accommodation and photophobia, transient bradycardia followed by tachycardia, with palpitations and arrhythmias, and difficulty in micturition.


¤ In case of over-dosage, anti-cholinergic symptoms as

  • urinary retention, dry mouth, reddening of the skin, tachycardia and transient visual disturbances may occur.

Treatment of the over-dosage:

  • gastric lavage with medicinal charcoal should be  followed by magnesium sulfate (15%). In addition, appropriate supportive therapy should be given as required. 


  • 1- 2 tablets of Busconil® tablet three to five times a day as needed.


  • depending on age, the daily children dosage of Busconil® oral solution is recommended as follows:

-Children Over 6 years:

  • 10 ml 3- 4 times daily.

-Children 1- 6 years:

  • 5- 10 ml three times daily.

-Infants less than 1 year:

  • 5 ml three times daily.

¤ Busconil® can be taken both on empty and full stomach.

Busconil® needs to be used with caution in:

  • Patients prone to narrow angle glaucoma;
  • Patients susceptible to intestinal or urinary outlet obstructions;
  • In those inclined to tachyarrhythmia.
  • Busconil® tablet : Blister of 10 tablets, pack of two Blisters. 
  • Busconil® oral solution : bottles of 60 ml / 100 ml.

¤ Hospital packs of different sizes.

  • Store in a dry place at a temperature not exceeding 25°C.